Cytoskeletal reorganization and cell death in mitoxantrone-treated lung cancer cells

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
• Mitoxantrone (MXT) is an antineoplastic agent used in cancer therapy.
• Understanding drug mechanisms in different cancer cell lines is crucial for targeted therapy.

Purpose of the Study:

• To investigate the cytotoxic effects of mitoxantrone on A549 (p53+) and H1299 (p53-) human NSCLC cell lines.
• To evaluate the impact of mitoxantrone on cytoskeletal protein organization in these cell lines.
• To elucidate the cell death pathways triggered by mitoxantrone.

Main Methods:

• Cell culture of A549 and H1299 human non-small cell lung cancer lines.
• Treatment with varying concentrations of mitoxantrone.
• Analysis using fluorescence microscopy, transmission electron microscopy, spectrophotometry, flow cytometry, and Western blotting.

Main Results:

• H1299 cells exhibited significantly higher sensitivity to mitoxantrone compared to A549 cells.
• Mitoxantrone induced alterations in cytoskeletal organization, including ring-like microtubule structures and loss of actin stress fibers.
• Cell cycle arrest at the S phase was associated with increased susceptibility to mitoxantrone-induced cell death, primarily apoptosis, with necrosis and mitotic catastrophe observed at higher concentrations.

Conclusions:

• Mitoxantrone demonstrates differential cytotoxicity against NSCLC cell lines, with H1299 cells being more sensitive.
• The drug affects cytoskeletal organization, potentially through altered tubulin polymerization and actin dynamics.
• Mitoxantrone-induced cell death in NSCLC involves apoptosis, necrosis, and mitotic catastrophe, with S-phase arrest correlating with sensitivity.